Jacobs Levy Equity Management’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-303,051
| Closed | -$5.97M | – | 948 |
|
|
2025
Q3 | $5.97M | Sell |
303,051
-154,785
| -34% | -$3.18M | 0.02% | 389 |
|
|
2025
Q2 | $9.94M | Sell |
457,836
-48,609
| -10% | -$1.15M | 0.04% | 306 |
|
|
2025
Q1 | $12.3M | Sell |
506,445
-406,554
| -45% | -$9.16M | 0.05% | 300 |
|
|
2024
Q4 | $19.1M | Sell |
912,999
-144,391
| -14% | -$3.1M | 0.07% | 224 |
|
|
2024
Q3 | $21M | Sell |
1,057,390
-284,174
| -21% | -$5.27M | 0.08% | 223 |
|
|
2024
Q2 | $20.8M | Buy |
1,341,564
+85,684
| +7% | +$1.33M | 0.09% | 213 |
|
|
2024
Q1 | $20M | Sell |
1,255,880
-30,612
| -2% | -$461K | 0.09% | 209 |
|
|
2023
Q4 | $21.6M | Sell |
1,286,492
-20,733
| -2% | -$283K | 0.11% | 197 |
|
|
2023
Q3 | $15.3M | Sell |
1,307,225
-14,056
| -1% | -$188K | 0.09% | 210 |
|
|
2023
Q2 | $17.8M | Buy |
1,321,281
+102,287
| +8% | +$1.47M | 0.1% | 207 |
|
|
2023
Q1 | $20.2M | Buy |
1,218,994
+1,100,381
| +928% | +$18.2M | 0.12% | 188 |
|
|
2022
Q4 | $2.21M | Buy |
118,613
+5,190
| +5% | +$79.9K | 0.01% | 537 |
|
|
2022
Q3 | $1.46M | Sell |
113,423
-853,637
| -88% | -$10.1M | 0.01% | 625 |
|
|
2022
Q2 | $6.78M | Sell |
967,060
-277,970
| -22% | -$2.04M | 0.05% | 358 |
|
|
2022
Q1 | $10.3M | Buy |
1,245,030
+71,181
| +6% | +$503K | 0.07% | 286 |
|
|
2021
Q4 | $7.95M | Buy |
1,173,849
+437,929
| +60% | +$2.88M | 0.05% | 345 |
|
|
2021
Q3 | $3.9M | Sell |
735,920
-54,229
| -7% | -$297K | 0.03% | 485 |
|
|
2021
Q2 | $4.54M | Sell |
790,149
-348,462
| -31% | -$1.8M | 0.03% | 449 |
|
|
2021
Q1 | $5.25M | Buy |
1,138,611
+801,397
| +238% | +$3.18M | 0.04% | 411 |
|
|
2020
Q4 | $1.13M | Buy |
337,214
+113,140
| +50% | +$380K | 0.01% | 695 |
|
|
2020
Q3 | $665K | Sell |
224,074
-19,576
| -8% | -$76.6K | 0.01% | 735 |
|
|
2020
Q2 | $1.13M | Sell |
243,650
-4,766
| -2% | -$21.4K | 0.01% | 647 |
|
|
2020
Q1 | $956K | Buy |
248,416
+23,751
| +11% | +$97.5K | 0.01% | 629 |
|
|
2019
Q4 | $842K | Buy |
224,665
+6,965
| +3% | +$32.6K | 0.01% | 717 |
|
|
2019
Q3 | $1.16M | Buy |
217,700
+161,300
| +286% | +$859K | 0.01% | 596 |
|
|
2019
Q2 | $217K | Buy |
56,400
+1,500
| +3% | +$6.48K | ﹤0.01% | 866 |
|
|
2019
Q1 | $280K | Sell |
54,900
-10,300
| -16% | -$30.3K | ﹤0.01% | 846 |
|
|
2018
Q4 | $125K | Buy |
+65,200
| New | +$187K | ﹤0.01% | 931 |
|
|
2018
Q3 | – | Sell |
-47,400
| Closed | -$148K | – | 1002 |
|
|
2018
Q2 | $148K | Buy |
+47,400
| New | +$144K | ﹤0.01% | 976 |
|
|
2016
Q2 | – | Sell |
-25,800
| Closed | -$30K | – | 1164 |
|
|
2016
Q1 | $30K | Buy |
+25,800
| New | +$40K | ﹤0.01% | 1077 |
|
Other funds holding CPRX
DM
Jacobs Levy Equity Management's CPRX Position: Q4 2025 in Review
Jacobs Levy Equity Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 303,051 shares — an estimated $5.97M sold.
Jacobs Levy Equity Management first reported a position in CPRX in Q1 2016 and held it in 30 quarters. The position peaked at $21.6M in Q4 2023. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.
- Jacobs Levy Equity Management reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
- Jacobs Levy Equity Management sold 303,051 Catalyst Pharmaceutical shares in Q4 2025, an estimated $5.97M.
- Jacobs Levy Equity Management first reported a position in Catalyst Pharmaceutical in Q1 2016 and held it in 30 quarters.
- Jacobs Levy Equity Management's Catalyst Pharmaceutical position peaked at $21.6M in Q4 2023.
- 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.
Based on Jacobs Levy Equity Management's 13F filing for Q4 2025, filed 13 Feb 2026.